Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer
- 30 April 2004
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 44 (1) , 121-127
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Recommendation for Caution with Irinotecan, Fluorouracil, and Leucovorin for Colorectal CancerNew England Journal of Medicine, 2001
- Effect of bile acids on the uptake of irinotecan and its active metabolite, SN-38, by intestinal cellsBiochimica et Biophysica Acta (BBA) - General Subjects, 2001
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cellsInternational Journal of Cancer, 1999
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerThe Lancet, 1998
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998
- Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancerCancer Chemotherapy and Pharmacology, 1998
- In vitro investigation of a combination of two drugs, cisplatin and carboplatin, as a function of the area under thec/t curveJournal of Cancer Research and Clinical Oncology, 1995
- Inhibition of cis‐diamminedichloroplatinum (II)‐induced DNA interstrand cross‐link removal by 7‐ethyl‐10‐hydroxy‐camptothecin in HST‐1 human squamous‐carcinoma cellsInternational Journal of Cancer, 1995